Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma

BACKGROUND: Targeted drugs including bevacizumab, cetuximab, and panitumumab have been widely used during the management of patients diagnosed with colorectal carcinoma, especially as palliative treatment. The present meta-analysis was performed to evaluate the fatal adverse events (FAEs) of targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui, Ni, Tao, He, Huijuan, Zheng, Qinhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310739/
https://www.ncbi.nlm.nih.gov/pubmed/32569154
http://dx.doi.org/10.1097/MD.0000000000019908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310739/
https://www.ncbi.nlm.nih.gov/pubmed/32569154
http://dx.doi.org/10.1097/MD.0000000000019908

Ejemplares similares